Saracatinib and Alcohol Drinking

Completed · Phase 2 · Has a placebo group

Conditions studied: Alcohol Drinking

In brief

The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.

Key facts

Study ID

NCT02955186

Run by

Yale University

People needed

50

Starts

2017-05-09

Expected to finish

2019-06-07

Last updated by the study team

2020-11-13

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ages 21-50
• Able to read English at 6th grade level or higher and to complete study evaluations
• Regular alcohol drinker

You may not qualify if…

• Individuals who are seeking alcohol treatment
• Medical conditions that would contraindicate the use of saracatinib
• Regular use of other substances

Where it is running

• CMHC, Substance Abuse Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.